scholarly journals George Wells Beadle, 23 October 1903 - 9 June 1989

1995 ◽  
Vol 41 ◽  
pp. 44-54
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nobel Prize ◽  
Experimental Work ◽  
University Of Chicago ◽  
Academic Administrator ◽  
Distinguished Career ◽  
The University ◽  
Classical Genetics

George Wells Beadle was born to Hattie Albro and Chauncey Elmer Beadle in Wahoo, Nebraska, on 22 October 1903. He died in Pomona, California, on 9 June 1989. Beadle was one of the giant figures of genetics in our time. He initiated the series of great discoveries made between 1941 and 1953 that brought to a close the era of classical genetics and launched the molecular age. For this achievement, he received many honours, including the Nobel Prize. Beadle also had a distinguished career as an academic administrator. When he retired in 1968, he was President of the University of Chicago. He never lost his love of experimental genetics, however, and after his retirement he resumed experimental work on a favourite subject: the origin of maize. In 1981, he gave up research because of increasing disability from the Alzheimer’s disease that eventually ended his life.

scholarly journals MALCOLM EDWIN JEWELL

2010 ◽  
Vol 43 (03) ◽  
pp. 585-587
Author(s):  
Bradley C. Canon
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Political Parties ◽  
Political Science ◽  
The Political ◽  
Legislative Behavior ◽  
Science Department ◽  
University Of Kentucky ◽  
Political Science Department ◽  
The University

Malcolm “Mac” Jewell was a mainstay of the Political Science Department at the University of Kentucky (UK) for 36 years. For that same period and even longer, he was one of the profession's leading researchers in explaining legislative behavior (particularly in the states) and how state political parties worked. Mac retired from UK in 1994 but continued being active in our profession. Around 2004, he began suffering from Alzheimer's disease. He died on February 24, 2010, in Fairfield, Connecticut.

scholarly journals Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer’s disease progression that reinforces the 2018 NIA-AA research framework

2018 ◽  
Author(s):  
Priya Devanarayan ◽  
Viswanath Devanarayan ◽  
Daniel A. Llano ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Multiple Reaction Monitoring ◽  
Pharmaceutical Research ◽  
Normal Subjects ◽  
Hippocampal Volume ◽  
National Institutes Of Health ◽  
Decision Threshold ◽  
Research Framework ◽  
The University

AbstractThe 2018 NIA-AA research framework proposes a classification system with beta-Amyloid deposition, pathologic Tau, and neurodegeneration (ATN) for the diagnosis and staging of Alzheimer’s Disease (AD). Data from the ADNI (AD neuroimaging initiative) database can be utilized to identify diagnostic signatures for predicting AD progression, and to determine the utility of this NIA-AA research framework. Profiles of 320 peptides from baseline cerebrospinal fluid (CSF) samples of 287 normal, mild cognitive impairment (MCI) and AD subjects followed over a 3-10 year period were measured via multiple reaction monitoring (MRM) mass spectrometry. CSF Aβ42, total-Tau (tTau), phosphorylated-Tau (pTau-181) and hippocampal volume were also measured. From these candidate markers, optimal diagnostic signatures with decision thresholds to separate AD and normal subjects were first identified via unbiased regression and tree-based algorithms. The best performing signature determined via cross-validation was then tested in an independent group of MCI subjects to predict future progression. This multivariate analysis yielded a simple diagnostic signature comprising CSF pTau-181 to Aβ42 ratio, MRI hippocampal volume and a novel PTPRN peptide, with a decision threshold on each marker. When applied to a separate MCI group at baseline, subjects meeting this signature criteria experience 4.3-fold faster progression to AD compared to a 2.2-fold faster progression using only conventional markers. This novel 4-marker signature represents an advance over the current diagnostics based on widely used marker, and is much easier to use in practice than recently published complex signatures. In addition, this signature reinforces the ATN construct from the 2018 NIA-AA research framework.DisclosuresViswanath Devanarayan is an employee of Charles River Laboratories, and as such owns equity in, receives salary and other compensation from Charles River Laboratories.Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.;Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

scholarly journals A semi-automated pipeline for fulfillment of resource requests from a longitudinal Alzheimer's disease registry

JAMIA Open ◽  
2019 ◽  
Vol 2 (4) ◽  
pp. 516-520
Author(s):  
Katelyn A McKenzie ◽  
Suzanne L Hunt ◽  
Genevieve Hulshof ◽  
Dinesh Pal Mudaranthakam ◽  
Kayla Meyer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Data Management ◽  
Reproducible Research ◽  
University Of Kansas ◽  
Data Set ◽  
Data Accessibility ◽  
Monthly Data ◽  
Variable List ◽  
The University

Abstract Objective Managing registries with continual data collection poses challenges, such as following reproducible research protocols and guaranteeing data accessibility. The University of Kansas (KU) Alzheimer’s Disease Center (ADC) maintains one such registry: Curated Clinical Cohort Phenotypes and Observations (C3PO). We created an automated and reproducible process by which investigators have access to C3PO data. Materials and Methods Data was input into Research Electronic Data Capture. Monthly, data part of the Uniform Data Set (UDS), that is data also collected at other ADCs, was uploaded to the National Alzheimer’s Coordinating Center (NACC). Quarterly, NACC cleaned, curated, and returned the UDS to the KU Data Management and Statistics (DMS) Core, where it was stored in C3PO with other quarterly curated site-specific data. Investigators seeking to utilize C3PO submitted a research proposal and requested variables via the publicly accessible and searchable data dictionary. The DMS Core used this variable list and an automated SAS program to create a subset of C3PO. Results C3PO contained 1913 variables stored in 15 datasets. From 2017 to 2018, 38 data requests were completed for several KU departments and other research institutions. Completing data requests became more efficient; C3PO subsets were produced in under 10 seconds. Discussion The data management strategy outlined above facilitated reproducible research practices, which is fundamental to the future of research as it allows replication and verification to occur. Conclusion We created a transparent, automated, and efficient process of extracting subsets of data from a registry where data was changing daily.

scholarly journals 7. Experimental work at the university of chicago on the onset of thermal instability in a layer of fluid heated from below

1958 ◽  
Vol 6 ◽  
pp. 61-70
Author(s):  
Yoshinari Nakagawa ◽  
Kevin H. Prendergast
Keyword(s):  
Rayleigh Number ◽  
Experimental Work ◽  
Thermal Instability ◽  
University Of Chicago ◽  
Administrative Supervision ◽  
Theoretical Investigations ◽  
Theoretical Predictions ◽  
S Chandrasekhar ◽  
The University ◽  
Better Than

This paper will summarize the experimental work at the University of Chicago on the problem of the onset of thermal instability in a layer of fluid heated from below. The purpose of this work has been to test certain theoretical predictions of the Rayleigh number at which instability sets in, and to determine the type of instability which appears at the critical point. The earlier experiments of this series were done at the hydrodynamics laboratory of the University of Chicago in connexion with a program of meteorological reseach[1, 2, 3, 4]. The current work is being done at the newly organized hydromagnetics laboratory of the Enrico Fermi Institute of Nuclear Studies. This laboratory utilizes the magnet of the old Chicago cyclotron, with pole pieces 92·7 cm in diameter and a gap of 22·1 cm. The magnet was reconstructed to allow the field strength to be varied from 0 to 13,000 gauss; the field is uniform to better than 1 % over the experimental area. The new laboratory is under the administrative supervision of Professors S. K. Allison and S. Chandrasekhar; the experiments are being done by Y. Nakagawa. The theoretical investigations are primarily the work of Chandrasekhar[5, 6, 7, 8, 9, 10] and it will be convenient to review some of his results before discussing the experiments.

Comparison of Alzheimer's Disease in Native Americans and Whites

2003 ◽  
Vol 15 (4) ◽  
pp. 367-375 ◽  
Author(s):  
Myron F. Weiner ◽  
Roger N. Rosenberg ◽  
Doris Svetlik ◽  
Linda S. Hynan ◽  
Kyle B. Womack ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Native American ◽  
Native Americans ◽  
Age At Onset ◽  
Course Of Illness ◽  
University Of Texas ◽  
Disease Clinic ◽  
Prevalence Of Depression ◽  
The University

Objective: This study compared medical history and findings on initial clinical examination in Native Americans diagnosed with possible or probable Alzheimer's disease (AD) at Native American satellite clinics of the University of Texas (UT) Southwestern Medical Center's Alzheimer's Disease Center with those of Whites diagnosed with probable AD at the UT Southwestern Medical Center's Alzheimer's Disease Clinic. Methods: The information reviewed was contained in the database of the UT Southwestern Alzheimer's Disease Center. Results: In relation to Whites, Native Americans had slightly but significantly greater age at onset of symptoms (71.7 vs. 69.6 years, t = −2.08, p = .04) and equivalent cognitive scores at evaluation (Mini-Mental State Exam score = 17.4 vs. 18.5, t = 0.98, p = .33), despite significantly lower educational level (11.4 vs. 13.4 years, t = 5.63, p < .001). Native Americans were more frequently depressed on examination (22.8% vs. 9.5%, χ2 = 12, p = .001) and reported diabetes, hypertension, and heart disease significantly more often than did Whites (p < .01 for all), but their survival time after AD diagnosis was similar to that of Whites despite these comorbidities. Conclusions: With the exception of a greater prevalence of depression and cardiovascular risk factors in Native Americans than in Whites, Native Americans had a course of illness similar to that of Whites.

scholarly journals The Challenges of Diagnosis in Alzheimer’s Disease

US Neurology ◽  
2018 ◽  
Vol 14 (1) ◽  
pp. 15 ◽  
Author(s):  
Nenad Bogdanovic
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Beta ◽  
Amyloid Pet ◽  
Positive Finding ◽  
Positron Emission ◽  
University Of Oslo ◽  
The University ◽  
Study Participants ◽  
The Brain

Current neuropathologic examination of the brain is still the gold standard for diagnosis of Alzheimer’s disease (AD). Postmortem studies, however, have indicated that current methods for the clinical diagnosis of AD are suboptimal.1Recent research has demonstrated the clinical utility of amyloid-beta positron emission tomography (PET) scans, which detect the presence of amyloid-beta plaques in the brain. In a study presented at the Alzheimer’s Association International Conference (AAIC) in London, UK, July 2017, by Nenad Bogdanovic, MD, PhD, of the University of Oslo in Norway, amyloid PET imaging was found to be a fundamental diagnostic tool for AD, establishing a definite diagnosis or excluding AD in all 50 study participants.2 The use of cerebrospinal fluid (CSF) amyloid testing with a higher amyloid-beta plaque threshold than that traditionally used to establish a positive finding also resulted in high diagnostic accuracy, resulting in diagnosis or exclusion in 44 of 50 participants (88%) compared with only 21 individuals (42%) using traditional cutoffs.2

scholarly journals Disparities Research at the Deep South Alzheimer’s Disease Center of the University of Alabama at Birmingham

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 100-100
Author(s):  
Maria Pisu ◽  
David Geldmacher
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
South Carolina ◽  
African American ◽  
African Americans ◽  
Deep South ◽  
Medicare Beneficiaries ◽  
University Of Alabama ◽  
The Us ◽  
The University

Abstract Residents of the US Deep South (Alabama, Georgia, Louisiana, Mississippi, and South Carolina) have a 20–30% higher risk of developing Alzheimer’s disease or related dementia (ADRD). Moreover, &gt;20% of African Americans, who are at higher ADRD risk than whites, live in this region. Therefore, one important goals of the Deep South Alzheimer’s Disease Center (DS-ADC) of the University of Alabama at Birmingham is to spearhead research to address these disparities. This panel presents current DS-ADC research, with two presentations focusing on the local patient population and the last two on the Deep South population compared to the rest of the nation. Addressing the challenge of recruiting representative samples in clinical research, the first paper is part of a research program to understand difference that may exist between African American and white research participants. The second paper examines patients with multiple conditions, in particular dementia and cancer, showing a marked disadvantage in cognition outcomes for African Americans. The next two papers take a broader perspective to better understand the population of older adults with ADRD in the Deep South and in the rest of the US. The third paper examines socioeconomic and medical contexts of African American and white older Medicare beneficiaries with ADRD, and the fourth paper examines differences in utilization of specialists, ADRD drugs, and hospitalizations in the two regions taking these contexts into account. The discussant will close the session by placing these studies in the larger context of the disparities research at the DS-ADC.

Sign in / Sign up

Export Citation Format

Share Document